Structural diversity of the epigenetics pocketome

Proteins: Structure, Function and Bioinformatics

Volumn 83, Issue 7, 2015, Pages 1316-1326

  Cabaye, Alexandre ^a,c   Nguyen, Kong T ^a,d   Liu, Lihua ^a   Pande, Vineet ^b   Schapira, Matthieu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Proteorex Therapeutics Inc   (Canada)

Author keywords

Binding pocket; Chromatin factors; Drug design; Epigenetics; Inhibitor; Pocketome; Selectivity; Structure

Indexed keywords

ACYLTRANSFERASE; DNA; HISTONE; LYSINE ACETYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE; RNA; SIRTUIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHROMATIN; LIGAND; MOLECULAR LIBRARY; PROTEIN BINDING; TUMOR PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; DRUG BINDING SITE; DRUG TARGETING; EPIGENETIC POCKETOME; EPIGENETICS; GENETIC DISTANCE; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DATA BANK; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN STRUCTURE; TRANSPORT AND BINDING PHENOMENA; VALIDATION STUDY; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; CHROMATIN; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; INTERNET; MOLECULAR LIBRARY; MOLECULAR MODEL; NEOPLASMS; PATHOLOGY; PHARMACOLOGY; PROTEIN DATABASE; PROTEIN TERTIARY STRUCTURE; SOFTWARE; SYNTHESIS;

ACETYLTRANSFERASES; ANTINEOPLASTIC AGENTS; BINDING SITES; CHROMATIN; DATABASES, PROTEIN; DNA, NEOPLASM; EPIGENESIS, GENETIC; HISTONES; HUMANS; INTERNET; LIGANDS; MODELS, MOLECULAR; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTEIN-ARGININE N-METHYLTRANSFERASES; RNA, NEOPLASM; SIRTUINS; SMALL MOLECULE LIBRARIES; SOFTWARE;

EID: 84931010257     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24830     Document Type: Article

References (32)

1. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012;13:484-492.
2. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705.
3. Xhemalce B, Robson SC, Kouzarides T. Human RNA methyltransferase BCDIN3D regulates microRNA processing. Cell 2012;151:278-288.
4. Nilsen TW. Molecular biology. Internal mRNA methylation finally finds functions. Science 2014;343:1207-1208.
5. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012;11:384-400.
6. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008;123:8-13.
7. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25:84-90.
8. Copeland RA. Molecular pathways: protein methyltransferases in cancer. Clin Cancer Res 2013;19:6344-6350.
9. Liu L, Zhen XT, Denton E, Marsden BD, Schapira M. ChromoHub: a data hub for navigators of chromatin-mediated signalling. Bioinformatics 2012;28:2205-2206.
10. Totrov M. Ligand binding site superposition and comparison based on atomic property fields: identification of distant homologues, convergent evolution and PDB-wide clustering of binding sites. BMC Bioinform 2011;12: S35
11. Siarheyeva A, Senisterra G, Allali-Hassani A, Dong A, Dobrovetsky E, Wasney GA, Chau I, Marcellus R, Hajian T, Liu F, Korboukh I, Smil D, Bolshan Y, Min J, Wu H, Zeng H, Loppnau P, Poda G, Griffin C, Aman A, Brown PJ, Jin J, Al-Awar R, Arrowsmith CH, Schapira M, Vedadi M. An allosteric inhibitor of protein arginine methyltransferase 3. Structure 2012;20:1425-1435.
12. Schapira M. Structural biology of human metal-dependent histone deacetylases. Handb Exp Pharmacol 2011;206:225-240.
13. Schuetz A, Min J, Allali-Hassani A, Schapira M, Shuen M, Loppnau P, Mazitschek R, Kwiatkowski NP, Lewis TA, Maglathin RL, McLean TH, Bochkarev A, Plotnikov AN, Vedadi M, Arrowsmith CH. Human hdac7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem 2008;283:11355-11363.
14. Campagna-Slater V, Mok MW, Nguyen KT, Feher M, Najmanovich R, Schapira M. Structural chemistry of the histone methyltransferases cofactor binding site. J Chem Inf Model 2011;51:612-623.
15. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 2009;8:724-732.
16. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 2014;13:337-356.
17. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, Fedorov O, Brennan P, Bunnage ME, Owen DR, Bradner JE, Taniere P, O'Sullivan B, Muller S, Schwaller J, Stankovic T, Knapp S. PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res 2013;73:3336-3346.
18. Hay DA, Fedorov O, Martin S, Singleton DC, Tallant C, Wells C, Picaud S, Philpott M, Monteiro OP, Rogers CM, Conway SJ, Rooney TP, Tumber A, Yapp C, Filippakopoulos P, Bunnage ME, Muller S, Knapp S, Schofield CJ, Brennan PE. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc 2014;136:9308-9319.
19. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, DPA, 3rd Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108-112.
20. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, Moyer MP, Richon VM, Copeland RA, Keilhack H, Pollock RM, Kuntz KW. A selective inhibitor of ezh2 blocks h3k27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012;8:890-896.
21. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC, Kung AL, Armstrong SA, Copeland RA, Richon VM, Pollock RM. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011;20:53-65.
22. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, Al-Awar R, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH, Bradner JE, Schapira M. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012;3:1288.
23. Basavapathruni A, Jin L, Daigle SR, Majer CR, Therkelsen CA, Wigle TJ, Kuntz KW, Chesworth R, Pollock RM, Scott MP, Moyer MP, Richon VM, Copeland RA, Olhava EJ. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des 2012;80:971-980.
24. Antonysamy S, Bonday Z, Campbell RM, Doyle B, Druzina Z, Gheyi T, Han B, Jungheim LN, Qian Y, Rauch C, Russell M, Sauder JM, Wasserman SR, Weichert K, Willard FS, Zhang A, Emtage S. Crystal structure of the human prmt5:mep50 complex. Proc Natl Acad Sci USA 2012;109:17960-17965.
25. Schapira M, Ferreira de Freitas R. Structural biology and chemistry of protein arginine methyltransferases. Med Chem Commun 2014;5:1779-1788.
26. Schapira M. Structural chemistry of human SET domain protein methyltransferases. Curr Chem Genomics 2012;5:85-94.
27. Fischle W, Wang Y, Allis CD. Binary switches and modification cassettes in histone biology and beyond. Nature 2003;425:475-479.
28. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 2007;14:1025-1040.
29. James LI, Frye SV. Targeting chromatin readers. Clin Pharmacol Ther 2013;93:312-314.
30. Gao C, Herold JM, Kireev D, Wigle T, Norris JL, Frye S. Biophysical probes reveal a "compromise" nature of the methyl-lysine binding pocket in l3mbtl1. J Am Chem Soc 2011;133:5357-5362.
31. Lu R, Wang GG. Tudor: a versatile family of histone methylation 'readers'. Trends Biochem Sci 2013;38:546-555.
32. Min J, Allali-Hassani A, Nady N, Qi C, Ouyang H, Liu Y, MacKenzie F, Vedadi M, Arrowsmith CH. L3mbtl1 recognition of mono- and dimethylated histones. Nat Struct Mol Biol 2007;14:1229-1230.